B7-H4 treatment of t cells inhibits erk, jnk, p38, and akt activation

Xiaojie Wang, Jianqiang Hao, Daniel L. Metzger, Ziliang Ao, Lieping Chen, Dawei Ou, C. Bruce Verchere, Alice Mui, Garth L. Warnock

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


B7-H4 is a newly identified B7 homolog that plays an important role in maintaining T-cell homeostasis by inhibiting T-cell proliferation and lymphokine-secretion. In this study, we investigated the signal transduction pathways inhibited by B7-H4 engagement in mouse T cells. We found that treatment of CD3 + T cells with a B7-H4.Ig fusion protein inhibits anti-CD3 elicited T-cell receptor (TCR)/CD28 signaling events, including phosphorylation of the MAP kinases, ERK, p38, and JNK. B7-H4.Ig treatment also inhibited the phosphorylation of AKT kinase and impaired its kinase activity as assessed by the phosphorylation of its endogenous substrate GSK-3. Expression of IL-2 is also reduced by B7-H4. In contrast, the phosphorylation state of the TCR proximal tyrosine kinases ZAP70 and lymphocyte-specific protein tyrosine kinase (LCK) are not affected by B7-H4 ligation. These results indicate that B7-H4 inhibits T-cell proliferation and IL-2 production through interfering with activation of ERK, JNK, and AKT, but not of ZAP70 or LCK.

Original languageEnglish (US)
Article numbere28232
JournalPLoS One
Issue number1
StatePublished - Jan 4 2012
Externally publishedYes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)


Dive into the research topics of 'B7-H4 treatment of t cells inhibits erk, jnk, p38, and akt activation'. Together they form a unique fingerprint.

Cite this